Skip to main content

Table 1 Distribution of 4492 study subjects by selected characteristics at enrolment; diagnosis of hepatocellular carcinoma (HCC) at follow-up; HCC incidence rates and hazard ratios for HCC with 95 % confidence intervals (CI). Naples, 2003–2012

From: Infection with hepatitis viruses, FIB-4 index and risk of hepatocellular carcinoma in southern Italy: a population-based cohort study

Characteristics at enrolment Study subjects HCC cases Incidence Rate/105 (95 % CI) Hazard Ratios (95 % CI)b
No. No.
Total 4492 22 63.3 (41.7–96.2)  
Gender
 Female 2482 10 51.4 (27.6–95.5) 1*
 Male 2010 12 78.5 (44.6–138.3) 1.2 (0.5–2.7)
Age at testing (years)
 < 60 3349 3 11.3 (3.6–35.0) 1*
 60–69 551 9 214.7 (111.7–412.6) 7.5 (1.8–30.8)
 ≥ 70 592 10 252.8 (136.0–469.8) 6.8 (1.6–29.3)
Chronic HCV/HBV infections**
 Anti HCV-negative/HBsAg-negative 4065 2 6.3 (0.8–22.8) 1*
 HCV RNA-negative/HBsAg-positive 95 3 403.3 (83.2–1179) 75.0 (12.3–456.5)
 HCV RNA-positive/HBsAg-negative 239 15 909.3 (509.0–1500) 61.8 (13.3–286.4)
 HCV RNA-positive/HBsAg-positive 4 0 0.0 (0.0–11,938) 0.0 (0.0-∞)
γ-glutamyl transferase (γGT) U/La
 ≤ 30 3588 9 32.2 (16.8–61.9) 1*
 31–90 784 5 83.9 (34.9–201.6) 1.5 (0.5–4.7)
 > 90 116 8 1006 (503.0–2011) 10.3 (3.6–29.2)
Alanine transaminase (ALT) U/La
 ≤ 40 3954 8 26.1 (13.1–52.2) 1*
 41–120 490 9 240.1 (125.0–461.5) 4.1 (1.5–11.4)
 > 120 45 5 1598 (665–3840) 10.3 (3.2–33.3)
Aspartate aminotransferase (AST) U/La
 ≤ 40 4294 6 18.0 (8.1–40.0) 1*
 41–120 170 11 885.1 (490.2–1598) 9.4 (3.1–28.8)
 > 120 25 5 3539 (1473–8501) 27.4 (7.6–98.0)
Platelet count (103/μl)a
 220–700 2253 2 11.4 (1.4–41.1) 1*
 < 220 2203 20 118.4 (72.3–182.8) 50.0 (1.0–100.0)
FIB-4a
 < 1.45 3552 1 3.6 (0.5–25.4) 1*
 1.45–3.25 774 5 88.3 (36.8–212.2)
 > 3.25 130 16 1889 (1157–3083) 17.6 (6.2–49.7)
  1. aThe sum does not add up to the total because of missing values; badjusted for gender, age, chronic HCV/HBV infections – except FIB-4, which was adjusted for gender and chronic HCV/HBV infections since age is included in the index; *reference category; **89 HCV-positive, RNA-negative study subjects who developed 2 HCC cases were excluded